Asia Pacific Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)
The Asia Pacific Anti-Obesity Drugs Market is projected to grow significantly, reaching approximately US$ 15,476.6 million by 2031, up from US$ 1,317.2 million in 2024, with an estimated compound annual growth rate (CAGR) of 45.7% from 2025 to 2031.
Executive Summary and Market Analysis
The market is divided into several regions, including China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Key drivers of market growth include:
Market Segmentation Analysis:
Emerging economies present substantial opportunities for the anti-obesity drugs market due to increasing obesity rates driven by urbanization and lifestyle changes. Enhanced healthcare infrastructure and rising awareness of obesity-related health risks are fueling demand for effective treatments. Pharmaceutical companies are increasingly investing in these markets to address the unmet need for weight management solutions. For instance, a Lancet study from July 2023 predicts that by 2050, around 450 million adults in India will be overweight or obese.
Countries like Vietnam, Indonesia, and Bangladesh are also witnessing rising obesity rates, with prevalence rates of 6-9% in recent decades. The demand for anti-obesity drugs is growing as a significant portion of the population remains undiagnosed or untreated, creating a market ripe for pharmaceutical innovation. Eli Lilly, for example, plans to launch its weight-loss drug tirzepatide in India, Brazil, and Mexico by 2026.
Brazil is improving its healthcare infrastructure and obesity management programs, creating a favorable environment for new anti-obesity medications. While initial access to these drugs may be limited to private markets and out-of-pocket payments, future insurance coverage and generic options could enhance accessibility.
Country Insights
By country, the Asia Pacific Anti-Obesity Drugs Market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC, with China holding the largest market share in 2024. Obesity is a significant public health issue in China, with over 50% of adults and around 20% of children classified as overweight. Projections indicate that by 2030, 65% of the population may be overweight. This crisis has prompted both governmental and corporate efforts to find effective solutions, leading to increased investments in anti-obesity treatments.
Company Profiles
Key players in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence.
Executive Summary and Market Analysis
The market is divided into several regions, including China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Key drivers of market growth include:
- Urbanization and Sedentary Lifestyles: Increased urban living and sedentary habits have led to rising obesity rates, particularly in countries like China, India, and Australia.
- Economic Development: Rapid economic growth has resulted in higher consumption of calorie-dense, processed foods.
- Health Awareness: There is a growing recognition of the health risks associated with obesity, such as diabetes, cardiovascular diseases, and certain cancers, which has increased the demand for effective weight management solutions.
- Government Initiatives: Programs promoting healthier lifestyles and preventive healthcare are aiding market expansion.
- Pharmaceutical Advancements: Innovations in drug research and improved healthcare access are making anti-obesity medications more available.
- Rising Incomes: Increasing disposable incomes and a growing middle class in emerging markets are further driving demand.
- Cultural Shifts: Changing societal attitudes towards body image are motivating individuals to seek pharmacological weight loss options.
Market Segmentation Analysis:
- By Type: The market is categorized into Prescription Drugs and OTC Drugs, with Prescription Drugs holding the largest market share in 2024.
- By Mechanism of Action: Segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others, with Centrally Acting Drugs leading in market share.
- By Drug Class: Includes GLP-1 Agonists, Lipase Inhibitors, MC4R Agonists, and Others, where GLP-1 Agonists dominate.
- By GLP-1 Agonist: Further divided into Semaglutide, Liraglutide, and Tirzepatide (Zepbound), with Semaglutide being the most prominent.
- By Application: Categories include Appetite Suppression, Inhibition of Fat Absorption, Metabolic Enhancement, and Combination, with Appetite Suppression being the largest segment.
- By Route of Administration: Oral and Parenteral, with Oral being the preferred method.
- By Distribution Channel: Hospital Pharmacies, Online Channels, and Retail Pharmacies, with Hospital Pharmacies leading.
Emerging economies present substantial opportunities for the anti-obesity drugs market due to increasing obesity rates driven by urbanization and lifestyle changes. Enhanced healthcare infrastructure and rising awareness of obesity-related health risks are fueling demand for effective treatments. Pharmaceutical companies are increasingly investing in these markets to address the unmet need for weight management solutions. For instance, a Lancet study from July 2023 predicts that by 2050, around 450 million adults in India will be overweight or obese.
Countries like Vietnam, Indonesia, and Bangladesh are also witnessing rising obesity rates, with prevalence rates of 6-9% in recent decades. The demand for anti-obesity drugs is growing as a significant portion of the population remains undiagnosed or untreated, creating a market ripe for pharmaceutical innovation. Eli Lilly, for example, plans to launch its weight-loss drug tirzepatide in India, Brazil, and Mexico by 2026.
Brazil is improving its healthcare infrastructure and obesity management programs, creating a favorable environment for new anti-obesity medications. While initial access to these drugs may be limited to private markets and out-of-pocket payments, future insurance coverage and generic options could enhance accessibility.
Country Insights
By country, the Asia Pacific Anti-Obesity Drugs Market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC, with China holding the largest market share in 2024. Obesity is a significant public health issue in China, with over 50% of adults and around 20% of children classified as overweight. Projections indicate that by 2030, 65% of the population may be overweight. This crisis has prompted both governmental and corporate efforts to find effective solutions, leading to increased investments in anti-obesity treatments.
Company Profiles
Key players in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTI-OBESITY DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.1 PEST Analysis
5. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTI-OBESITY DRUGS MARKET - ASIA PACIFIC MARKET ANALYSIS
6.1 Asia Pacific Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
6.2 Asia Pacific Anti-Obesity Drugs Market Forecast and Analysis
7. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE
7.1 Prescription Drugs
7.1.1 Overview
7.1.2 Prescription Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 OTC Drugs
7.2.1 Overview
7.2.2 OTC Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION
8.1 Centrally Acting Drugs
8.1.1 Overview
8.1.2 Centrally Acting Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Peripherally Acting Drugs
8.2.1 Overview
8.2.2 Peripherally Acting Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS
9.1 GLP-1 Agonist
9.1.1 Overview
9.1.2 GLP-1 Agonist: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Lipase Inhibitors
9.2.1 Overview
9.2.2 Lipase Inhibitors: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 MC4R agonist
9.3.1 Overview
9.3.2 MC4R agonist: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST
10.1 Semaglutide
10.1.1 Overview
10.1.2 Semaglutide: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Liraglutide
10.2.1 Overview
10.2.2 Liraglutide: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Tirzepatide (Zepbound)
10.3.1 Overview
10.3.2 Tirzepatide (Zepbound): Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION
11.1 Appetite Suppression
11.1.1 Overview
11.1.2 Appetite Suppression: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2 Inhibition of Fat Absorption or Digestive Enzymes
11.2.1 Overview
11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3 Metabolic Enhancement
11.3.1 Overview
11.3.2 Metabolic Enhancement: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4 Combination
11.4.1 Overview
11.4.2 Combination: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
12.1 Oral
12.1.1 Overview
12.1.2 Oral: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12.2 Parenteral
12.2.1 Overview
12.2.2 Parenteral: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
13.1 Hospital Pharmacies
13.1.1 Overview
13.1.2 Hospital Pharmacies: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.2 Online Channel
13.2.1 Overview
13.2.2 Online Channel: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.3 Retail Pharmacies
13.3.1 Overview
13.3.2 Retail Pharmacies: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS
14.1 Asia Pacific
14.1.1 Asia Pacific Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.1.1 Asia Pacific Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.2.2 China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.1.2.2.1 China: Asia Pacific Anti-Obesity Drugs Market Share - by Type
14.1.2.2.2 China: Asia Pacific Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.1.2.2.3 China: Asia Pacific Anti-Obesity Drugs Market Share - by Drug Class
14.1.2.2.4 China: Asia Pacific Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.1.2.2.5 China: Asia Pacific Anti-Obesity Drugs Market Share - by Application
14.1.2.2.6 China: Asia Pacific Anti-Obesity Drugs Market Share - by Route Of Administration
14.1.2.2.7 China: Asia Pacific Anti-Obesity Drugs Market Share - by Distribution Channel
14.2.3.3 Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.2.3.3.1 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by Type
14.2.3.3.2 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.2.3.3.3 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by Drug Class
14.2.3.3.4 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.2.3.3.5 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by Application
14.2.3.3.6 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by Route Of Administration
14.2.3.3.7 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by Distribution Channel
14.3.4.4 India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.3.4.4.1 India: Asia Pacific Anti-Obesity Drugs Market Share - by Type
14.3.4.4.2 India: Asia Pacific Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.3.4.4.3 India: Asia Pacific Anti-Obesity Drugs Market Share - by Drug Class
14.3.4.4.4 India: Asia Pacific Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.3.4.4.5 India: Asia Pacific Anti-Obesity Drugs Market Share - by Application
14.3.4.4.6 India: Asia Pacific Anti-Obesity Drugs Market Share - by Route Of Administration
14.3.4.4.7 India: Asia Pacific Anti-Obesity Drugs Market Share - by Distribution Channel
14.4.5.5 Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.4.5.5.1 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by Type
14.4.5.5.2 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.4.5.5.3 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by Drug Class
14.4.5.5.4 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.4.5.5.5 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by Application
14.4.5.5.6 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by Route Of Administration
14.4.5.5.7 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by Distribution Channel
14.5.6.6 South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.5.6.6.1 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by Type
14.5.6.6.2 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.5.6.6.3 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by Drug Class
14.5.6.6.4 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.5.6.6.5 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by Application
14.5.6.6.6 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by Route Of Administration
14.5.6.6.7 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by Distribution Channel
14.6.7.7 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.6.7.7.1 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by Type
14.6.7.7.2 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.6.7.7.3 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by Drug Class
14.6.7.7.4 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.6.7.7.5 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by Application
14.6.7.7.6 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by Route Of Administration
14.6.7.7.7 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by Distribution Channel
15 COMPETITIVE LANDSCAPE
15.1 Heat Map Analysis by Key Players
15.2 Company Positioning & Concentration
16 INDUSTRY LANDSCAPE
16.1 Overview
16.2 New Product Development
16.3 Merger and Acquisition
16.4 Other Strategic Developments
17 COMPANY PROFILES
17.1 GSK Plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
17.2 F. Hoffmann-La Roche Ltd
17.2.1 Key Facts
17.2.2 Business Description
17.2.3 Products and Services
17.2.4 Financial Overview
17.2.5 SWOT Analysis
17.2.6 Key Developments
17.3 Teva Pharmaceutical Industries Ltd
17.3.1 Key Facts
17.3.2 Business Description
17.3.3 Products and Services
17.3.4 Financial Overview
17.3.5 SWOT Analysis
17.3.6 Key Developments
17.4 Novo Nordisk AS
17.4.1 Key Facts
17.4.2 Business Description
17.4.3 Products and Services
17.4.4 Financial Overview
17.4.5 SWOT Analysis
17.4.6 Key Developments
17.5 Eli Lilly and Co
17.5.1 Key Facts
17.5.2 Business Description
17.5.3 Products and Services
17.5.4 Financial Overview
17.5.5 SWOT Analysis
17.5.6 Key Developments
17.6 Sun Pharmaceutical Industries Ltd
17.6.1 Key Facts
17.6.2 Business Description
17.6.3 Products and Services
17.6.4 Financial Overview
17.6.5 SWOT Analysis
17.6.6 Key Developments
17.7 VIVUS LLC
17.7.1 Key Facts
17.7.2 Business Description
17.7.3 Products and Services
17.7.4 Financial Overview
17.7.5 SWOT Analysis
17.7.6 Key Developments
17.8 Currax Pharmaceuticals LLC.
17.8.1 Key Facts
17.8.2 Business Description
17.8.3 Products and Services
17.8.4 Financial Overview
17.8.5 SWOT Analysis
17.8.6 Key Developments
17.9 AdvaCare Pharma USA LLC
17.9.1 Key Facts
17.9.2 Business Description
17.9.3 Products and Services
17.9.4 Financial Overview
17.9.5 SWOT Analysis
17.9.6 Key Developments
17.10 Rhythm Pharmaceuticals Inc
17.10.1 Key Facts
17.10.2 Business Description
17.10.3 Products and Services
17.10.4 Financial Overview
17.10.5 SWOT Analysis
17.10.6 Key Developments
18. APPENDIX
18.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTI-OBESITY DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.1 PEST Analysis
5. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTI-OBESITY DRUGS MARKET - ASIA PACIFIC MARKET ANALYSIS
6.1 Asia Pacific Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
6.2 Asia Pacific Anti-Obesity Drugs Market Forecast and Analysis
7. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE
7.1 Prescription Drugs
7.1.1 Overview
7.1.2 Prescription Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 OTC Drugs
7.2.1 Overview
7.2.2 OTC Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION
8.1 Centrally Acting Drugs
8.1.1 Overview
8.1.2 Centrally Acting Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Peripherally Acting Drugs
8.2.1 Overview
8.2.2 Peripherally Acting Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS
9.1 GLP-1 Agonist
9.1.1 Overview
9.1.2 GLP-1 Agonist: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Lipase Inhibitors
9.2.1 Overview
9.2.2 Lipase Inhibitors: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 MC4R agonist
9.3.1 Overview
9.3.2 MC4R agonist: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST
10.1 Semaglutide
10.1.1 Overview
10.1.2 Semaglutide: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Liraglutide
10.2.1 Overview
10.2.2 Liraglutide: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Tirzepatide (Zepbound)
10.3.1 Overview
10.3.2 Tirzepatide (Zepbound): Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION
11.1 Appetite Suppression
11.1.1 Overview
11.1.2 Appetite Suppression: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2 Inhibition of Fat Absorption or Digestive Enzymes
11.2.1 Overview
11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3 Metabolic Enhancement
11.3.1 Overview
11.3.2 Metabolic Enhancement: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4 Combination
11.4.1 Overview
11.4.2 Combination: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
12.1 Oral
12.1.1 Overview
12.1.2 Oral: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12.2 Parenteral
12.2.1 Overview
12.2.2 Parenteral: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
13.1 Hospital Pharmacies
13.1.1 Overview
13.1.2 Hospital Pharmacies: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.2 Online Channel
13.2.1 Overview
13.2.2 Online Channel: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.3 Retail Pharmacies
13.3.1 Overview
13.3.2 Retail Pharmacies: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS
14.1 Asia Pacific
14.1.1 Asia Pacific Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.1.1 Asia Pacific Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.2.2 China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.1.2.2.1 China: Asia Pacific Anti-Obesity Drugs Market Share - by Type
14.1.2.2.2 China: Asia Pacific Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.1.2.2.3 China: Asia Pacific Anti-Obesity Drugs Market Share - by Drug Class
14.1.2.2.4 China: Asia Pacific Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.1.2.2.5 China: Asia Pacific Anti-Obesity Drugs Market Share - by Application
14.1.2.2.6 China: Asia Pacific Anti-Obesity Drugs Market Share - by Route Of Administration
14.1.2.2.7 China: Asia Pacific Anti-Obesity Drugs Market Share - by Distribution Channel
14.2.3.3 Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.2.3.3.1 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by Type
14.2.3.3.2 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.2.3.3.3 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by Drug Class
14.2.3.3.4 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.2.3.3.5 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by Application
14.2.3.3.6 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by Route Of Administration
14.2.3.3.7 Japan: Asia Pacific Anti-Obesity Drugs Market Share - by Distribution Channel
14.3.4.4 India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.3.4.4.1 India: Asia Pacific Anti-Obesity Drugs Market Share - by Type
14.3.4.4.2 India: Asia Pacific Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.3.4.4.3 India: Asia Pacific Anti-Obesity Drugs Market Share - by Drug Class
14.3.4.4.4 India: Asia Pacific Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.3.4.4.5 India: Asia Pacific Anti-Obesity Drugs Market Share - by Application
14.3.4.4.6 India: Asia Pacific Anti-Obesity Drugs Market Share - by Route Of Administration
14.3.4.4.7 India: Asia Pacific Anti-Obesity Drugs Market Share - by Distribution Channel
14.4.5.5 Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.4.5.5.1 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by Type
14.4.5.5.2 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.4.5.5.3 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by Drug Class
14.4.5.5.4 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.4.5.5.5 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by Application
14.4.5.5.6 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by Route Of Administration
14.4.5.5.7 Australia: Asia Pacific Anti-Obesity Drugs Market Share - by Distribution Channel
14.5.6.6 South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.5.6.6.1 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by Type
14.5.6.6.2 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.5.6.6.3 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by Drug Class
14.5.6.6.4 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.5.6.6.5 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by Application
14.5.6.6.6 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by Route Of Administration
14.5.6.6.7 South Korea: Asia Pacific Anti-Obesity Drugs Market Share - by Distribution Channel
14.6.7.7 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.6.7.7.1 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by Type
14.6.7.7.2 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.6.7.7.3 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by Drug Class
14.6.7.7.4 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.6.7.7.5 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by Application
14.6.7.7.6 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by Route Of Administration
14.6.7.7.7 Rest of APAC: Asia Pacific Anti-Obesity Drugs Market Share - by Distribution Channel
15 COMPETITIVE LANDSCAPE
15.1 Heat Map Analysis by Key Players
15.2 Company Positioning & Concentration
16 INDUSTRY LANDSCAPE
16.1 Overview
16.2 New Product Development
16.3 Merger and Acquisition
16.4 Other Strategic Developments
17 COMPANY PROFILES
17.1 GSK Plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
17.2 F. Hoffmann-La Roche Ltd
17.2.1 Key Facts
17.2.2 Business Description
17.2.3 Products and Services
17.2.4 Financial Overview
17.2.5 SWOT Analysis
17.2.6 Key Developments
17.3 Teva Pharmaceutical Industries Ltd
17.3.1 Key Facts
17.3.2 Business Description
17.3.3 Products and Services
17.3.4 Financial Overview
17.3.5 SWOT Analysis
17.3.6 Key Developments
17.4 Novo Nordisk AS
17.4.1 Key Facts
17.4.2 Business Description
17.4.3 Products and Services
17.4.4 Financial Overview
17.4.5 SWOT Analysis
17.4.6 Key Developments
17.5 Eli Lilly and Co
17.5.1 Key Facts
17.5.2 Business Description
17.5.3 Products and Services
17.5.4 Financial Overview
17.5.5 SWOT Analysis
17.5.6 Key Developments
17.6 Sun Pharmaceutical Industries Ltd
17.6.1 Key Facts
17.6.2 Business Description
17.6.3 Products and Services
17.6.4 Financial Overview
17.6.5 SWOT Analysis
17.6.6 Key Developments
17.7 VIVUS LLC
17.7.1 Key Facts
17.7.2 Business Description
17.7.3 Products and Services
17.7.4 Financial Overview
17.7.5 SWOT Analysis
17.7.6 Key Developments
17.8 Currax Pharmaceuticals LLC.
17.8.1 Key Facts
17.8.2 Business Description
17.8.3 Products and Services
17.8.4 Financial Overview
17.8.5 SWOT Analysis
17.8.6 Key Developments
17.9 AdvaCare Pharma USA LLC
17.9.1 Key Facts
17.9.2 Business Description
17.9.3 Products and Services
17.9.4 Financial Overview
17.9.5 SWOT Analysis
17.9.6 Key Developments
17.10 Rhythm Pharmaceuticals Inc
17.10.1 Key Facts
17.10.2 Business Description
17.10.3 Products and Services
17.10.4 Financial Overview
17.10.5 SWOT Analysis
17.10.6 Key Developments
18. APPENDIX
18.1 About The Insight Partners
LIST OF TABLES
Table 1. Asia Pacific Anti-Obesity Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 6. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 7. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 8. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 9. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 10. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 11. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 12. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 13. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 14. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 15. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 16. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 18. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 19. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 21. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 22. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 23. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 25. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 26. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 27. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 28. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 29. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 30. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 31. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 32. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 33. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 34. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 35. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 36. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 37. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 38. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 39. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 40. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 41. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 42. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 43. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 44. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 45. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 46. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 47. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 48. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 49. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 50. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 51. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 52. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 53. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 54. Heat Map Analysis by Key Players
Table 1. Asia Pacific Anti-Obesity Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 6. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 7. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 8. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 9. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 10. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 11. Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 12. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 13. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 14. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 15. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 16. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 18. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 19. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 21. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 22. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 23. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 25. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 26. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 27. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 28. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 29. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 30. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 31. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 32. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 33. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 34. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 35. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 36. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 37. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 38. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 39. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 40. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 41. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 42. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 43. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 44. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 45. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 46. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 47. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 48. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 49. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 50. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 51. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 52. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 53. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 54. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Asia Pacific Anti-Obesity Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Anti-Obesity Drugs Market
Figure 4. Asia Pacific Anti-Obesity Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Asia Pacific Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
Figure 7. Asia Pacific Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. OTC Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Asia Pacific Anti-Obesity Drugs Market Share (%) - by Mechanism Of Action, 2024 and 2031
Figure 11. Centrally Acting Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Peripherally Acting Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Others: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Asia Pacific Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
Figure 15. GLP-1 Agonist: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Lipase Inhibitors: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. MC4R agonist: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Asia Pacific Anti-Obesity Drugs Market Share (%) - by GLP-1 Agonist, 2024 and 2031
Figure 20. Semaglutide: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Liraglutide: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Tirzepatide (Zepbound): Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Asia Pacific Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031
Figure 24. Appetite Suppression: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Metabolic Enhancement: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Combination: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Asia Pacific Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 29. Oral: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Parenteral: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Asia Pacific Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 32. Hospital Pharmacies: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Online Channel: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 34. Retail Pharmacies: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 35. Asia Pacific Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 36. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 37. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 38. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 39. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 40. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 41. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 42. Company Positioning & Concentration
Figure 1. Asia Pacific Anti-Obesity Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Anti-Obesity Drugs Market
Figure 4. Asia Pacific Anti-Obesity Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Asia Pacific Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
Figure 7. Asia Pacific Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. OTC Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Asia Pacific Anti-Obesity Drugs Market Share (%) - by Mechanism Of Action, 2024 and 2031
Figure 11. Centrally Acting Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Peripherally Acting Drugs: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Others: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Asia Pacific Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
Figure 15. GLP-1 Agonist: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Lipase Inhibitors: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. MC4R agonist: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Asia Pacific Anti-Obesity Drugs Market Share (%) - by GLP-1 Agonist, 2024 and 2031
Figure 20. Semaglutide: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Liraglutide: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Tirzepatide (Zepbound): Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Asia Pacific Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031
Figure 24. Appetite Suppression: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Metabolic Enhancement: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Combination: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Asia Pacific Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 29. Oral: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Parenteral: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Asia Pacific Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 32. Hospital Pharmacies: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Online Channel: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 34. Retail Pharmacies: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 35. Asia Pacific Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 36. China: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 37. Japan: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 38. India: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 39. Australia: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 40. South Korea: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 41. Rest of APAC: Asia Pacific Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 42. Company Positioning & Concentration
